Allergy Therapeutics (LON:AGY) Sets New 12-Month High - Here's What Happened

Key Points

• Allergy Therapeutics shares reached a new 52-week high of GBX 8.75 ($0.12), reflecting a significant milestone in trading.
• The company's market capitalization stands at £415.32 million, with notable metrics such as a P/E ratio of -8.14.
• Allergy Therapeutics specializes in the treatment of allergic disorders, offering aluminium-free immunotherapy vaccines across various European countries.

Allergy Therapeutics plc (LON:AGY - ) shares hit a new 52-week high during trading on Monday . The company traded as high as GBX 8.75 ($0.12) and last traded at GBX 8.45 ($0.11), with a volume of 609349 shares trading hands. The stock had previously closed at GBX 8.75 ($0.12).

Allergy Therapeutics Trading Down 3.4%

The business's 50-day moving average price is GBX 7.70 and its 200 day moving average price is GBX 6.95. The company has a market cap of £415.32 million, a P/E ratio of -8.14, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.